SUBSCRIBE
SUBSCRIBE
Tristan Manalac

Tristan Manalac

Contributing Writer | News

Tristan is an independent science writer based in Metro Manila, with more than eight years of experience writing about medicine, biotech and science. Being formally trained in molecular biology, he once dreamed of collecting degrees and starting his own lab. But these days, he finds his greatest joy in a bottle of beer and a beautiful sentence. He can be reached at tristan.manalac@biospace.com, tristan@tristanmanalac.com or on LinkedIn.

AbbVie's office in South San Francisco, California
AbbVie Tops Doctor Ranking of Immunology Companies, Handily Beating Pfizer and J&J
Bolstered by its portfolio of “revolutionary” therapies, AbbVie remains the top pharma company in the immunology space, according to a new survey of doctors by ZoomRx.
April 22, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: Vifor Pharma's office in Switzerland/iSt
Policy
CSL Vifor Offers Marketing Campaign to Reverse Alleged Anti-Competitive Practices
Following an investigation regarding antitrust practices against Pharmacosmos’ Monofer, CSL Vifor has proposed a sweeping multi-channel communication campaign designed to reverse allegedly misleading messages about its rival.
April 22, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: Doctor looking at a patient's MRI brain scan
Drug Development
AbbVie, NeuroDerm Heat Up Levodopa Competition with New Data at AAN24
As AbbVie and NeuroDerm race toward potential U.S. approvals later this year, the companies presented strong data at last week’s American Academy of Neurology 2024 annual meeting for their respective continuous subcutaneous levodopa infusions.
April 22, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: Businessmen shaking hands after closing a deal
Business
Alvotech, Teva Enlist New Partner to Expand Access to Humira Biosimilar in US
Ahead of launching its Humira biosimilar Simlandi, Alvotech and Teva on Friday announced they have signed a long-term agreement with an undisclosed strategic partner to help boost patient access to the drug.
April 19, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: Facade of Sanofi's headquarters in Franc
Business
Sanofi Cuts Jobs in US Vaccines Division as Part of Restructuring
French healthcare and pharma company Sanofi will terminate an undisclosed number of positions in its U.S. vaccines commercial unit in an effort to streamline the strategic sales structure.
April 19, 2024
 · 
2 min read
 · 
Tristan Manalac
Signage outside Genentech's headquarters in Silicon Valley
FDA
Genentech Wins FDA Approval for First Adjuvant Therapy for ALK-Positive, Early NSCLC
Roche’s subsidiary Genentech has successfully expanded the label of Alecensa to include the adjuvant treatment of anaplastic lymphoma kinase-positive, early-stage non-small cell lung cancer following resection.
April 19, 2024
 · 
2 min read
 · 
Tristan Manalac
FDA signage at its office in Maryland
Policy
FDA Requires Boxed Warning for Secondary Cancers on CAR-T Therapies
Following a months-long safety review, the regulator on Thursday said it is now requiring updated black box warnings for all commercially available CAR-T therapies to reflect the risk of secondary malignancies.
April 19, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: A scientist with pill bottles in front of FDA headquarters/Taylor Tieden for BioSpace
Policy
FDA Action Alert: ImmunityBio, Aquestive, XOMA and More
The FDA will close out April with five target action dates around indications that include pediatric seizures and a neurological cancer in children.
April 18, 2024
 · 
6 min read
 · 
Tristan Manalac
Pictured: Roche Diagnostics building in California
Drug Development
Roche’s Ocrevus Achieves Near-Complete Reduction of Relapse, Lesions in MS
Data from the Phase III OCARINA II study shows the subcutaneous version of Ocrevus achieved near-complete suppression of relapses and brain lesions in relapsing or primary progressive multiple sclerosis.
April 18, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: FDA signage at its office in Washington, DC
FDA
Teva, Alvotech Secure FDA Approval for Stelara Biosimilar with Early 2025 Launch
Teva Pharmaceuticals and Alvotech got the FDA’s greenlight for their biosimilar to Johnson & Johnson’s blockbuster Stelara, which will launch in the U.S. in February 2025.
April 18, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: Eli Lilly's headquarters in Indianapolis
Drug Development
Most Doses of Lilly’s Zepbound and Mounjaro in Short Supply Through Q2: FDA
Nearly all doses of Eli Lilly’s highly popular weight-loss drug Zepbound and type 2 diabetes medication Mounjaro will have limited availability through the second quarter of 2024, according to the regulator.
April 18, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: Magnetic resonance imaging scans of the brain
Drug Development
Cerevel Gets Phase III Parkinson’s Win on Heels of $8.7B AbbVie Acquisition
Cerevel Therapeutics on Thursday reported positive data from its Phase III TEMPO-3 trial, showing that tavapadon can significantly improve symptom control in patients with Parkinson’s disease.
April 18, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: Eli Lilly's biotechnology center in San Diego, California
Drug Development
Lilly Eyes Zepbound Label Expansion After Clearing Phase III Sleep Apnea Study
With Wednesday’s readout showing symptom improvements in obstructive sleep apnea patients, Eli Lilly is preparing to file for a label expansion for its blockbuster weight-loss drug Zepbound.
April 17, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: Illustration of antibodies attacking a nerve cell
Drug Development
Cullinan Targets Autoimmune Market, Nabs $280M in Private Placement
Cullinan Oncology, now renamed Cullinan Therapeutics, is riding the growing wave of interest in autoimmune disorders by refocusing its bispecific T cell-engager CLN-978 for systemic lupus erythematosus.
April 17, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: Gloved hand holding a collection tube for a triglyceride test
Drug Development
Arrowhead’s Plozasiran Poised for Dyslipidemia Market, $700M in Sales by 2032: GlobalData
On the heels of a Phase IIb win, Arrowhead Pharmaceuticals’ plozasiran could fulfill a critical unmet need in dyslipidemia treatment bringing in $707 million in sales by 2032, according to data analytics firm GlobalData.
April 17, 2024
 · 
2 min read
 · 
Tristan Manalac
Load More